<i>IL28B</i> polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4

Antaki, Nabil; Bibert, Stéphanie; Kebbewar, Kamel; Asaad, Fouad; Baroudi, O; Alideeb, S; Hadad, M.; Abboud, Dirar; Sabah, Houda; Bochud, Pierre–Yves; Negro, Francesco

doi:10.1111/j.1365-2893.2012.01621.x

Cited by 39 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were 51 studies with a total of 11,102 HCV-4 patients included in the primary analysis (Table 1)[10–16, 18, 27, 28, 34, 35, 37–42, 45, 46, 48, 53–56, 59, 62, 63, 65–67, 69, 71–73, 75–81, 83–85, 88, 90, 91, 93, 95, 96]. The majority of studies (40/51, 78%) originated from the Middle East[10–13, 15, 16, 18, 27, 28, 34, 35, 37, 40–42, 45, 46, 53–56, 59, 62, 63, 66, 67, 69, 72, 75, 78, 80, 81, 83–85, 88, 91, 95] and Europe (9/51, 18%)[14, 38, 39, 65, 71, 76, 79, 93, 96].…”

Section: Resultsmentioning

confidence: 99%

“…The majority of studies (40/51, 78%) originated from the Middle East[10–13, 15, 16, 18, 27, 28, 34, 35, 37, 40–42, 45, 46, 53–56, 59, 62, 63, 66, 67, 69, 72, 75, 78, 80, 81, 83–85, 88, 91, 95] and Europe (9/51, 18%)[14, 38, 39, 65, 71, 76, 79, 93, 96]. One originated in Cameroon[77] and one multi-center study was conducted in 19 countries[73].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis

Yee

Nguyen

Zhang

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background The burden of hepatitis C virus genotype 4 (HCV-4) is high in Africa and East Mediterranean countries. Previous reports estimate sustained virologic response (SVR) rates in HCV-4 to be ~20–70%. However, many of these studies are limited by different study designs and small sample sizes. Aim Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN+RBV) in a systematic and quantitative fashion. Methods A comprehensive literature search in MEDLINE and EMBASE for ‘genotype 4’ was conducted in November 2013. Abstracts from AASLD, APASL, DDW, and EASL in 2012/2013 were reviewed. Inclusion criteria were original studies with ≥25 treatment-naïve HCV-4 patients treated with PEG IFN+RBV. Exclusion criteria were co-infection with HIV, HBV, or other genotypes. Effect sizes were calculated using random-effects models. Heterogeneity was determined by Cochrane Q-test (p-value <0.05) and I-squared statistic (>50%). Results We included 51 studies (11,102 HCV-4 patients) in the primary analysis. Pooled SVR was 53% (95% CI: 50–55%) (Q-statistic = 269.20, p<0.05; I2 = 81.43). On sub-group analyses, SVR was significantly associated with lower viral load, OR 3.05 (CI 1.80–5.17, p<0.001); mild fibrosis, OR 3.17 (CI 2.19–4.59, p<0.001); and favorable IL28B polymorphisms, rs12979860 CC versus CT/TT, OR 4.70 (CI 2.87–7.69, p<0.001), and rs8099917 TT versus GT/GG, OR 5.21 (CI 2.31–11.73, p<0.001). Conclusions HCV-4 patients treated with PEG IFN+RBV may expect SVR rate of ~50%. Lower viral load, mild fibrosis, and favorable IL28B (rs12979860 CC and rs8099917 TT) are positively associated with SVR.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Meta-analysis

Yee

Nguyen

Zhang

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…(68% from Egypt) (Ge et al, 2009a), 82 patients from different ethnic groups (51% Egyptians, 34% Europeans and 13.4% SubSaharan Africans) (Asselah et al, 2012), 201 cases from Qatar and 182 from Syria (Antaki et al, 2013), were all analyzed for a single SNP, rs12979860 (except for Antaki et al, who studied rs8099917 and rs12979860). The current study provides the largest study group to date with patients of the same ethnic group with genotype 4 and studies 3 SNPs in correlation with the cytokine IP-10.…”

Section: Discussionmentioning

confidence: 99%

The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients

et al. 2013

View full text Add to dashboard Cite

In genotype 4 cases, the IL28B SNPs rs12979860 rs8099917, and rs11881222 are the strongest predictors of a response, while IP-10 is a strong negative biomarker of a response. Accounting for this factor is important in the individualization of treatment and enhances the degree of predictiveness of the IL28 polymorphism in the final treatment outcome. The frequent distribution of C, A and T alleles of IL28 polymorphism are higher among TVR, which may reflect sensitivity to prolonged course.

show abstract

“…It has previously been clarified that host genetics play an essential role in clearing acute hepatitis C infection and achieving an SVR (32). Variants in the minor alleles, rs8099917 and rs12979860, are associated with SVR and natural viral clearance (33). In the present study of Chinese HCV-infected populations, the rate of T/T in rs8099917 and C/C in rs12979860 was significantly higher compared with the other two allelic genes (P<0.01) and was correlated with HCV genotype variation.…”

Section: Discussionmentioning

confidence: 99%

Correlation between the genetic variations in interleukin 28B and chronic hepatitis C virus genotypes in the Chinese population

Mao

Zhang

Chen

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Genetic variations at the interleukin 28B (IL-28B) locus and chronic hepatitis C virus (HCV) genotypes are significant factors in predicting the therapeutic outcome for HCV infection. The present study aimed to determine the geographical distribution of HCV genotypes and single nucleotide polymorphisms (SNPs) associated with IL-28B in Chinese patients infected with HCV. The gene frequencies of 13 types of IL-28B SNPs and HCV genotypes were investigated in 1,014 patients infected with HCV, who were recruited from varying regions of China. The correlation between the SNPs of IL-28B, the HCV genotypes and age, gender and geographical location were investigated. The data revealed geographical differences in age, gender and HCV genotypes in the Chinese HCV patients. HCV genotype 1 was distributed extensively and had a higher incidence compared with other HCV genotypes in all regions, with the exception of South (38%) and Northwest China (45.6%). A gender differences also existed (P<0.01). The distribution of genotype 6 was lower compared with other HCV genotypes in the majority of the regions (P<0.01). In middle-aged patients, the number of male patients was higher than the number of female patients in North and South China, which was the opposite of the results found in the other regions. There were no geographical differences in IL-28B SNPs in Chinese HCV-infected populations. Notably, there were significant differences between HCV genotype 1 and 2 in the genotype percentages of the majority of SNPs (P<0.01). In conclusion, a geographical distribution in HCV genotypes and a correlation between HCV genotypes and IL-28B SNPs have been identified, and indicate that these variants may be associated with spontaneous and treatment-induced HCV clearance.

show abstract

IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4

Cited by 39 publications

References 17 publications

Meta-analysis

Meta-analysis

The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients

Correlation between the genetic variations in interleukin 28B and chronic hepatitis C virus genotypes in the Chinese population

Contact Info

Product

Resources

About